Growth hormone / secretagogues
CJC-1295 (no DAC)
Research chemicalMod GRF 1-29 · Short-acting GHRH analog
Short-acting GHRH-analog research peptide, not FDA-approved.
What it is
A modified 29-amino-acid GHRH fragment that resists breakdown but lacks the albumin-binding linker, producing brief pulse-like GH release. Often paired with Ipamorelin anecdotally.
How it works
Activates pituitary GHRH receptors to stimulate a discrete pulse of endogenous GH.
Studied for
Endogenous GH/IGF-1 stimulation; body-composition claims anecdotal.
Regulatory status
Not FDA-approved; research chemical; WADA-prohibited.
Safety
Injection-site reactions, flushing, headache, water retention; raises IGF-1, can raise glucose.
What the community reports about CJC-1295 (no DAC)
Aggregated from real community discussions across social platforms and forums. Anecdotal and self-reported — not causal, not medical advice.
The default growth-hormone optimizer. CJC-1295 is a GHRH analog that signals the pituitary to release more of your own growth hormone, almost always paired with ipamorelin (a ghrelin mimetic) so the two amplify the natural pulse. It's reached for lean-muscle support, recovery, sleep and body composition.
- Reported: better sleep, visceral fat loss, recovery, recomp while cutting
- Recovery, sleep, skin quality and modest visceral-fat movement
- Mild hunger increase; DAC lingers and costs more
- Water retention signals dose crept too high or IGF-1 is rising
Aggregated from public discussions and community forums, synthesized into themes and counts. Anecdotal and self-reported — not causal, not evidence a compound is safe or effective, not medical advice, and not a recommendation to use. No dosing shown.
Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.